{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is DURECT Corp. technically bullish or bearish?
As of June 10, 2025, DURECT Corp. is in a mildly bearish trend, indicated by bearish daily moving averages and weekly KST signals, despite a mildly bullish MACD, with overall indicators suggesting weak upward momentum and uncertainty.
Who are in the management team of DURECT Corp.?
As of March 2022, the management team of DURECT Corp. includes David Hoffmann (Independent Chairman), James Brown (President and CEO), and Directors Mohammad Azab, Gail Maderis, Simon Benito, Terrence Blaschke, and Gail Farfel. They oversee the company's strategic direction and operations.
What does DURECT Corp. do?
Durect Corporation is a biopharmaceutical company focused on developing treatments for metabolic disorders and acute organ injuries. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $19.73 million.
How big is DURECT Corp.?
As of Jun 18, DURECT Corp. has a market capitalization of 19.73 million, with net sales of 4.87 million and a net profit of -13.87 million over the latest four quarters. Shareholder's funds are 9.13 million, and total assets are valued at 18.35 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
